Jiangsu Hualan New Pharmaceutical Material Co.Ltd(301093) independent director
Independent opinions on matters related to the 15th meeting of the 4th board of directors
In accordance with the company law, Shenzhen Stock Exchange self regulatory guidelines for listed companies No. 2 – standardized operation of GEM listed companies, articles of association and other relevant provisions, as an independent director of Jiangsu Hualan New Pharmaceutical Material Co.Ltd(301093) (hereinafter referred to as the “company”), we consulted the relevant materials provided by the company on the relevant proposals of the 15th meeting of the Fourth Board of directors, After knowing the relevant information and based on the position of independent judgment, the independent opinions are as follows:
1、 Independent opinion on the proposal on using some over raised funds to invest in the project of expanding the production capacity of pre filled medical packaging materials
After deliberation, we believe that it is necessary and reasonable for the company to use part of the over raised funds to invest in the project of expanding the production capacity of pre filled medical packaging materials, which is in line with the development direction of the company’s main business, conducive to the long-term development of the company and improve the use efficiency of the raised funds, in line with the interests of the company and all shareholders, The review procedures comply with the provisions of relevant laws and regulations, normative documents and the articles of association, such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the self discipline supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, There is no situation that damages the interests of the company and all shareholders, especially minority shareholders.
In conclusion, we agree that the company will use part of the over raised funds to invest in the project of expanding the production capacity of pre filled medical packaging materials, and agree to submit the above matters to the second extraordinary general meeting of shareholders of the company in 2022 for deliberation.
2、 Independent opinions on the proposal on the general election of the board of directors and the nomination of candidates for non independent directors of the Fifth Board of directors
After deliberation, we believe that:
1. The procedures for the general election of the board of directors are standardized and comply with the company law, the articles of association and other relevant provisions. 2. After the review of each director candidate, it is considered that this nomination is based on a full understanding of the nominee’s educational background, work experience, part-time work and professional quality, and has been approved by the nominee. The nominee has high professional knowledge and rich practical work experience, and has the qualification and ability to serve as a director of the company. There are no cases that the company law, the articles of association and other laws and regulations stipulate that they are not allowed to take office, there are no cases that the CSRC has confirmed that they are prohibited from entering the market and the prohibition has not been lifted, and they have not been punished by the CSRC and other relevant departments and the stock exchange.
Therefore, we agree to nominate Mr. Hua Guoping, Mr. Hua Yimin, Mr. Li Lun, Mr. Xiao Feng, Mr. Ma Weiguo and Mr. Wang Zhaoqian as candidates for non independent directors of the Fifth Board of directors of the company and submit them to the second extraordinary general meeting of shareholders of the company in 2022 for deliberation.
3、 Independent opinions on the proposal on the general election of the board of directors and the nomination of independent director candidates for the Fifth Board of directors
After deliberation, we believe that:
1. The procedures for the general election of the board of directors are standardized and comply with the company law, the articles of association and other relevant provisions. 2. After the review of each director candidate, it is considered that this nomination is based on a full understanding of the nominee’s educational background, work experience, part-time work and professional quality, and has been approved by the nominee. The nominee has high professional knowledge and rich practical work experience, and has the qualification and ability to serve as a director of the company. There are no cases that the company law, the articles of association and other laws and regulations stipulate that they are not allowed to take office, there are no cases that the CSRC has confirmed that they are prohibited from entering the market and the prohibition has not been lifted, and they have not been punished by the CSRC and other relevant departments and the stock exchange.
Therefore, we agree to nominate Mr. Liu Dan, Mr. Liu Li and Mr. Xu Zuojun as candidates for independent directors of the Fifth Board of directors of the company and submit them to the second extraordinary general meeting of shareholders of the company in 2022 for deliberation.
[there is no text on this page, which is the signature page of the independent opinions of Jiangsu Hualan New Pharmaceutical Material Co.Ltd(301093) independent directors on matters related to the 15th meeting of the Fourth Board of directors]
Yu Lixin (signature): Qiu Suo (signature):
Liu Dan (signature):
March 2, 2022
